Biotech · Wednesday, 18 November 2026
Written by AI agents built on Claude, from the sources they cite, and overseen by Zeemish. How it's made
This day: every beat The day in 11 minutes
The Trump administration pulls Heidi Overton's nomination to run the FDA, a day before a US Senate committee vote
Signals on this beat
Health agencies without settled heads High ↑
- The Trump administration pulled Heidi Overton, its pick to run the FDA, a day before a US Senate vote.
[1] - The NIH's infectious disease arm got a permanent head after going without one since 2025.
[6]
Big money for drug-finding tools Building ↑
- Isomorphic Labs raised $5 billion to design drugs with AI.
[12] - Eli Lilly agreed a deal worth up to $5.9 billion for Stipple Bio's cancer-target finder.
[16] - Flagship committed 100 million pounds to a London company-building lab.
[18]
Drugs that hit their target and fail High →
- Aclaris's eczema drug reached its target in the body and still did not clear skin.
[21] - Semaglutide changed Alzheimer's markers in trials but did not slow the disease.
[23]
Longer lives in hard illnesses Building ↑
- Children given Lembaz for Niemann-Pick disease lived a median of 8.5 years, against 4.9 without it.
[5] - A leukaemia vaccine raised median survival to 24 months from under 15.
[11]
The stories
22 on this beat today.
Each story is told in its parts: what happened, the questions that explain it, how it works, who gains and who pays, and the good news. A part appears when the sources give it.
-
01
The Trump administration pulls Heidi Overton's nomination to run the FDA, a day before a US Senate committee vote
1 day
between the pullout and the committee vote it was due to face
the vote was set for Wednesday 18 November
[3] 94 years
since Kansas had last elected a Democratic senator
the loser, Roger Marshall, is now a possible FDA pick
[1] What happened
-
The Trump administration withdrew Heidi Overton's nomination to run the FDA on Tuesday, an official said.
[1] [4] -
The pullout came 1 day before the US Senate health committee was due to vote on her.
[2] -
That vote decides whether a nominee goes on to a vote of the full US Senate.
[3] -
Lawmakers and health experts had questioned Overton's views on childhood vaccines, vaping and abortion.
[2] -
Bill Cassidy, the Republican senator who chairs the health committee, said on Tuesday he was still undecided.
[1] -
Cassidy then said the Trump administration had 'abandoned a viable confirmation path' for Overton.
[1] -
He said he believed she had the votes to pass the committee and then the whole US Senate.
[1] -
The Trump administration is now considering Senator Roger Marshall for the job, the Guardian reports, citing Reuters.
[1] -
He lost his race to stay in the US Senate, as Kansas elected its first Democratic senator in 94 years.
[1] -
Democrats take the US Senate majority in the new year, Democratic senator Chuck Schumer says.
[1] -
Cassidy said confirming a permanent FDA head will now fall to Senate Democrats.
[1]
Who is involved
The FDA is the US agency that checks that medicines and vaccines are safe and work.
[5] Overton is a doctor who advised President Trump on policy inside the US.
[2] Marshall is a doctor who cares for pregnant women, and like Overton he opposes abortion.
[1] He chairs the US Congress's group for Make America Healthy Again, the health drive Trump wanted Overton to advance.
[2] - Heidi Overton a doctor and President Trump's domestic policy adviser; his's pick to run the FDA, withdrawn
- Roger Marshall a Kansas senator and doctor who lost his seat; now being considered for the FDA
- The MAHA group in the US Congress Marshall chairs it
- Bill Cassidy the Republican senator for Louisiana who chairs the US Senate health committee; says she had the votes
- Kyle Diamantas the FDA's acting commissioner, who runs the agency for now
How it unfolded
Marty Makary, the FDA's last head, left in the spring.
[2] Reports said he fell out with President Trump over his reluctance to bring flavoured vapes back to US shops.
[2] Trump picked Overton in August and called her a 'rock star' of his government.
[2] - Tuesday nomination pulled
- Wednesday committee vote was due
-
Spring
Marty Makary leaves as FDA head
[2] - August Overton picked
- This week Overton pulled
-
New year
Democrats take the US Senate majority
[1] -
August
Trump picks Overton
[2] -
17 Nov
the Trump administration pulls her nomination
[1] -
18 Nov
the US Senate health committee vote had been due
[3]
Why it matters
For now the FDA is led by Kyle Diamantas, its acting commissioner.
[5] The FDA is also the agency that regulates abortion pills.
[1] Think it through
-
1
So what actually sank her?
Cassidy said anti-abortion senators wanted final promises on abortion from the Trump administration.
[1] It withdrew her rather than make them.[1] Anti-abortion senatorswanted promisesTrump administrationrefused -
2
Wasn't she against abortion pills already?
In 2023 Overton wrote that the US Congress should strictly regulate mifepristone, the main abortion pill.
[1] She wanted the pill tightly ruledSenators wanted it promisedNo promise came -
3
Who is glad she is gone?
Reproductive Freedom for All, a group backing abortion rights, celebrated the pullout.
[1] It said Overton threatened access to abortion pills.[1] -
4
Why look at a senator next?
An administration official told Semafor that senators traditionally have an easier time getting confirmed.
[1] 'At this point, it's hard to get anyone approved,' the official said.[1] -
5
So who now decides who runs the FDA?
President Trump still picks the nominee, and the US Senate must still approve.
[3] From the new year, Democrats will control that vote, Cassidy says.[1]
How it works
Public administration, the study of how governments are run, calls a stand-in boss an acting official. It means someone running a US agency without the US Senate's approval.
Kyle Diamantas, the FDA's acting official, announced a new drug approval on Tuesday.
[5] The NIH's infectious disease arm had an acting head from June until this week.[6] Seen it before
When a teacher is off sick, a supply teacher runs the class, but nobody expects them to rewrite the timetable.
The truth
-
What is really going on
The US drug regulator has no confirmed head, after the Trump administration pulled Heidi Overton rather than give anti-abortion senators promises.
[1] -
Why it works on people
Calling the pullout a matter of missing votes makes it sound like arithmetic, when the committee's own chair says the votes were there and the sticking point was a promise on abortion.
[1] - The Trump administration said Overton lacked the votes.
[1] Cassidy, who chairs the committee, says she had them.[1] -
Nobody knows yet
Who President Trump will nominate to run the FDA, and when.
Roger Marshall is only being considered, by the Guardian's account of a Reuters report, and no name has gone to the US Senate.
[1]
What comes next
Marshall is only being considered, and Democrats take the US Senate majority in the new year.
[1] -
The Trump administration withdrew Heidi Overton's nomination to run the FDA on Tuesday, an official said.
-
02
FDA approves the first drug to extend lives in Niemann-Pick C
What happened
-
The FDA approved Lembaz on Tuesday, for a rare inherited illness called Niemann-Pick disease type C.
[5] It is the first drug shown to help patients live longer.[5] -
In the illness, the body cannot handle cholesterol and other fats inside cells, so they pile up in the brain.
[5] -
It affects about 1 in 150,000 people, and is worst when symptoms start before age 6.
[5] -
Patients given Lembaz lived a median of 8.5 years.
[5] A matched group who did not get it lived 4.9 years.[5] -
A trained health worker injects it into the spinal canal every 2 weeks.
[5]
Why it matters
It lands on families of children with the worst form, after 2 older drugs were never shown to cut deaths.
[5] Think it through
-
1
How do you test it on so few children?
The FDA compared 36 treated patients, from 3 studies and a programme outside trials, with matched untreated patients.
[5] 36treated patients the FDA studied
-
2
What does it cost patients besides money?
Its label carries a boxed warning for hearing loss that can be permanent.
[5] Patients need hearing checks before and during treatment.[5] Longer life8.5 vs 4.9 yearsHearingcan be lost for good -
3
So who gets to have it?
The FDA's label limits it to patients weighing at least 7 kilograms whose symptoms began before age 6.
[5]
How it works
Trial designers call this an external control: patients outside the study, matched to those treated.
[5] With about 1 in 150,000 people affected, the FDA judged Lembaz's 36 patients against an external control.
[5] Seen it before
A coach judges a new drill by comparing this team with a similar team that never tried it.
The truth
- The survival gain rests on 36 patients compared with a matched outside group, not a group chosen by lot.
[5] -
Nobody knows yet
What Lembaz will cost, and so how many families can get it.
No price was given when the FDA announced the approval.
[5]
Good news
- Children with the worst form now have a drug that, in these patients, meant years of extra life.
[5]
-
The FDA approved Lembaz on Tuesday, for a rare inherited illness called Niemann-Pick disease type C.
-
03
The US officially loses measles-free status
What happened
-
On Tuesday the Pan American Health Organization ruled that measles is no longer eliminated in the US.
[7] It is the WHO's office for the Americas.[7] -
The US had been measles-free for 26 years, since 2000.
[8] -
The same body ruled measles is spreading again in Mexico and Bolivia.
[9] -
The US has had more than 5,400 cases this year, against 2,289 last year.
[8] -
A country loses the status when one chain of the same virus spreads for 12 months or more.
[9]
Who is involved
- US status lost
- Mexico status lost
- Bolivia status lost
Why it matters
It lands on children in places where fewer than 95% are vaccinated.
[8] Think it through
-
1
Why is it spreading now?
Only 92.4% of US kindergarteners got the measles vaccine last school year, below the 95% needed.
[8] - 1Kindergarteners vaccinated92.4%
- 2Needed95%
-
2
Who do people blame?
Critics say the CDC, the US disease agency, has run no national vaccination campaign.
[8] Health secretary Robert Kennedy Jr blamed Covid-era disruptions to childhood shots.[1] Criticsno national campaignKennedyblames Covid disruption -
3
Is a vaccine record always true?
In one hard-hit region of Bulgaria, about 60% of children recorded as vaccinated had no measles antibodies.
[10] Health officials say faked vaccination records play a part.[10] 60 of 100
about 60% of 'vaccinated' children unprotected
-
4
Can a country win it back?
Canada lost the status last year and declared its outbreak over in October.
[8] It must go a year without spread to win it back.[8] -
5
So who can actually stop it?
The CDC has sent $100 million to state and local health departments where measles is spreading.
[7] PAHO's part is to review a US plan.[8]
How it works
Epidemiologists call a disease eliminated in a country when no chain of local spread lasts a year.
[7] PAHO traced US cases from January 2025 and found a chain lasting at least 12 months.
[7] So measles is no longer eliminated there.[7] Seen it before
A school is called nit-free only after a whole term passes with no new case.
The truth
-
What is really going on
On the same day, the health body for the Americas ruled that measles is spreading in the US again.
[7] - The CDC lists 6 US measles deaths this year, while states have reported 10.
[7] -
Nobody knows yet
How long the US will take to win back measles-free status.
Good news
- Measles cases in the EU, Iceland, Liechtenstein and Norway fell to 2,325 in the year to September, from 10,195 the year before. No measles deaths were reported there by September.
What comes next
The US must send PAHO a plan to stop the spread in the coming weeks.
[8] -
On Tuesday the Pan American Health Organization ruled that measles is no longer eliminated in the US.
-
04
A leukaemia vaccine extends survival in a final trial
What happened
-
Sellas Life Sciences said its vaccine helped patients with acute myeloid leukaemia, a blood cancer, live longer.
[11] -
The result came from its last-stage trial, called phase 3.
[11] -
Patients lived a median of 24 months on the vaccine, against under 15 months on the best other treatment.
[11] -
The risk of death fell by 41%.
[11] -
The trial's 126 patients had leukaemia in remission, when the cancer retreats.
[11] Many had used up other treatments or could not have a stem cell transplant.[11] -
The vaccine, galinpepimut-S, targets WT1, a protein found in several kinds of tumour.
[11]
Why it matters
It lands on patients past most options, and was tested against chemotherapy and Venclexta, a drug from AbbVie and Roche.
[11] Think it through
-
1
Why did the answer take so long?
The final count needed 80 patient deaths, which were not reached until late October.
[11] 80deaths needed for the final count
-
2
Who stands to gain?
Sellas licensed the vaccine from Memorial Sloan Kettering, a cancer centre, and plans a speeded-up filing with the FDA.
[11] Cancer centre invents itSellas licenses itFaster FDA filing -
3
So who decides if patients get it?
The FDA does, on figures Sellas has so far given in its own announcement.
[11]
How it works
Cancer immunologists call this a cancer vaccine: a shot that teaches the immune system to attack a tumour's own protein.
Galinpepimut-S is a cancer vaccine aimed at WT1, which several tumour types carry.
[11] It was given to patients whose leukaemia was in remission.[11] Seen it before
A sniffer dog trained on one scent can pick out that one bag in a crowded airport.
The truth
- The trial set the vaccine against the best other treatment, not a dummy shot.
[11] Sellas has said only that safety was normal.[11]
Good news
- Patients on the vaccine lived more than 9 months longer at the median.
[11]
-
Sellas Life Sciences said its vaccine helped patients with acute myeloid leukaemia, a blood cancer, live longer.
-
05
Isomorphic raises $5 billion for AI drug design
What happened
-
Isomorphic Labs, a London drug-design firm, raised $5 billion on Tuesday.
[12] [13] -
It raised $2.1 billion only in May.
[12] -
Greenoaks and Sequoia Capital led the round, and Alphabet, Google's owner, invested heavily too.
[12] -
BioPharma Dive says it is the largest biotech round it has tracked since 2022.
[13]
Who is involved
It began at DeepMind, a sister company of Google, which built AlphaFold to predict protein shapes.
[12] - Alphabet the parent, investing again
Why it matters
The money is meant to move its drugs from computer models into tests in people.
[13] Think it through
-
1
Has its AI made a medicine yet?
No medicine designed by AI has been approved, BioPharma Dive notes.
[13] Isomorphic is still working toward testing its drugs in people.[12] -
2
So what are investors paying for?
Eli Lilly and Novartis signed deals with it worth about $3 billion in 2024, counting payments for goals met.
[12] $3 billionin deals with Lilly and Novartis
-
3
So who holds the power here?
Alphabet keeps funding it.
[12] Its partners Novartis, Johnson & Johnson and Lilly decide which of its designs to take forward.[13]
How it works
Structural biologists study the three-dimensional shapes of proteins, because a drug works by fitting a pocket on one.
Isomorphic says its engine beats AlphaFold 3 at predicting how a drug sits on a protein.
[12] So it does structural biology by computer, finding new pockets.[12] Seen it before
A key cut from a photo of a lock still has to turn in the real door.
The truth
- Isomorphic has called its early results 'positive' without publishing detailed data.
[12]
-
Isomorphic Labs, a London drug-design firm, raised $5 billion on Tuesday.
-
06
Marrow raises $173 million for sickle cell
What happened
-
Marrow Therapeutics, a new biotech, launched on Tuesday with $173 million to treat sickle cell disease and beta thalassaemia.
[15] [14] -
Its drug, MAR-101, is an antibody that carries a small piece of RNA into bone marrow cells.
[15] -
There it switches back on cells' ability to make a baby form of haemoglobin, the protein that carries oxygen.
[15] -
The drug has not yet been tested in people.
[14]
Who is involved
Both are inherited blood disorders.
[15] Why it matters
Today's gene treatments, Casgevy and Lyfgenia, cost millions and are given only at special centres.
[15] Most sickle cell patients are born in sub-Saharan Africa.[15] Think it through
-
1
Why an injection instead of gene editing?
Casgevy needs a patient's stem cells changed in a lab, plus chemotherapy first.
[15] MAR-101 would be a simple injection that can be repeated.[15] Casgevylab-made, chemo firstMAR-101a repeatable injection -
2
Who is paying for it?
Investors put in $54 million first, then $120 million in a round led by OrbiMed.
[14] Million dollars
First round54Second round120Marrow's two rounds -
3
So what must Marrow prove?
Earlier drugs built this way could not safely treat these disorders.
[15] Marrow must show safe doses reach bone marrow in people.[15] Earlier versions unsafeMarrow says it fixed itMust prove it in people
How it works
Molecular biologists call this gene silencing: a small RNA that turns one gene's output down.
MAR-101 uses gene silencing on BCL11A, a protein behind both diseases.
[14] With it lowered, cells make baby haemoglobin again.[15] Seen it before
Flicking an old light switch back on is easier than rewiring the house.
Why a drug can hit its target and still not help
Drug hunters call it target validation: proof that the molecule a drug hits really drives the illness, which hitting it does not prove.
The twist
A drug can grip its target perfectly and still fail, because the mistake was in the guess about the illness, not in the drug.
The picture
Drug reaches its targeta lab markerPatients do betteronly a trialThe left is what a blood or spinal fluid test can show early. The right is what decides whether the target mattered. Step by step
- Scientists guess which molecule drives an illness
- A drug is built to hit that molecule
- Tests show the drug hits it
- Only patients doing better shows the guess was right
The same force, elsewhere today
Where this chain is also running, in today's other stories.
-
Aclaris's eczema drug fails
bosakitug reached TSLP and lowered immune markers, yet skin scores did not move, so TSLP is the doubtful part
-
Weight-loss drugs and the brain
semaglutide moved Alzheimer's markers in the EVOKE trials without slowing the disease
-
AriBio's Alzheimer's pill
the pill raised its own marker in spinal fluid in everyone, but slowed decline only in one group
-
Marrow's sickle cell money
investors back a new drug aimed at a target that Casgevy's results already showed matters
Seen it before
Public policy
a scheme can hit every target it sets and leave the problem untouched, if the target was not the cause
Software debugging
a fix can change exactly the line it aimed at while the bug lives somewhere else
Farming
killing one pest works only if that pest, not the soil or weather, was eating the crop
The catch
A failed drug does not always clear its target: the wrong dose, the wrong patients or starting too late can sink a right guess too.
And the whole of it
Every pill on a pharmacy shelf rests on someone's guess about what causes an illness. Patients in today's trials are the ones still testing those guesses.
The truth
- Marrow has not said when MAR-101 will enter human trials.
[15] Until then, every claim rests on lab and animal data.[14]
-
Marrow Therapeutics, a new biotech, launched on Tuesday with $173 million to treat sickle cell disease and beta thalassaemia.
-
07
Lilly signs a $5.9 billion cancer target deal
What happened
-
Eli Lilly, a big US drugmaker, agreed a deal worth up to $5.9 billion with Stipple Bio, a cancer start-up.
[16] -
The $5.9 billion counts payments due only if goals are met, and the upfront sum is secret.
[16] -
Stipple raised $100 million in April and aims to start its first trials by 2029.
[16] -
Lilly has signed 3 other deals in 6 weeks, including buying Calytrix for up to $1.5 billion.
[16]
Who is involved
Stipple hunts for epitopes, tiny spots on a protein, that are found only on cancer cells.
[16] Why it matters
Drugs aimed at proteins like HER2 also hit healthy cells, which limits how much patients can take.
[16] Think it through
-
1
What does Lilly get?
Lilly gets exclusive world rights to any products from the work.
[16] -
2
Why pay before a drug exists?
Investors bet Stipple can widen the set of cancer targets a drug can be aimed at.
[16] -
3
So who holds the stronger hand?
Lilly holds the world rights and pays only as goals are met.
[16] Stipple holds the tool that finds the cancer-only spots.[16]
How it works
Oncologists call harm to healthy tissue that shares a drug's target on-target, off-tumour toxicity.
[16] HER2 sits on cancer cells and, in small amounts, healthy ones, so drugs aimed at it hurt both.
[16] Stipple aims at spots only cancer carries.[16] Seen it before
A weed killer that also hits the lawn can only be sprayed a little.
The truth
- Neither company gave the upfront payment, so how much Stipple is sure to get is unknown.
[16]
-
Eli Lilly, a big US drugmaker, agreed a deal worth up to $5.9 billion with Stipple Bio, a cancer start-up.
-
08
Seawolf launches with $100 million and a Sanofi deal
What happened
-
Seawolf Therapeutics, a San Diego gene therapy start-up, launched on Monday with $100 million.
[17] -
It also signed a deal with Sanofi, a big drugmaker, worth up to $1.2 billion in payments for goals met.
[17] -
Its backers include Eli Lilly, Novartis's venture fund and the investment arm of a bleeding-disorders charity.
[17] -
Seawolf packs DNA into fat bubbles called lipid nanoparticles to carry it into cells.
[17] -
The goal is to replace regular drug infusions with a dose every 6 months or every year.
[17]
Who is involved
- Lilly and Novartis drugmakers investing
- A bleeding-disorders charity investing through its fund
Why it matters
Patients who need regular infusions of proteins or antibodies could need far fewer visits.
[17] Think it through
-
1
Why not reuse the Covid-shot method?
The fat bubbles that work for RNA do not work well for DNA, the founder says.
[17] RNA bubbleswork for RNASame bubblespoor for DNA -
2
Why does a second dose matter?
Unlike AAV, a virus used in many gene therapies, Seawolf's method can be given again, its founder says.
[17] AAV virusgiven onceSeawolfcan be repeated -
3
So who gains if it works?
Sanofi gets an exclusive licence for bleeding disorders and other diseases.
[17]
How it works
Pharmacists call this drug delivery: getting a medicine into the right cells in one piece.
Seawolf's delivery system, Trident, packs DNA, a fat bubble and a helper protein into one package.
[17] Seen it before
A letter only works if the envelope gets it through the right letterbox unopened.
The truth
- The screen behind Trident was run in monkeys, so how it works in people is unknown.
[17]
-
Seawolf Therapeutics, a San Diego gene therapy start-up, launched on Monday with $100 million.
-
09
Flagship opens a 100 million pound lab in London
What happened
-
Flagship Pioneering, whose companies include Moderna, has committed 100 million pounds to a company-building lab in London.
[18] -
It is the first time Flagship has built companies outside its home of Cambridge, Massachusetts.
[18] -
The lab will hire about 50 scientist-entrepreneurs to start AI-based companies.
[18] -
Flagship hopes partners will add another 500 million pounds.
[18]
Why it matters
It follows AstraZeneca, Merck, Lilly and Sanofi pausing or reversing UK research spending last year.
[18] Think it through
-
1
Why did drugmakers pull back?
They objected to a UK scheme that sets how much is paid for medicines.
[18] -
2
Has that changed?
AstraZeneca restarted its UK investment after the rules were eased.
[18] Merck, Sanofi and Lilly say their stance has not changed.[18] AstraZenecainvesting againMerck, Sanofi, Lillyunchanged -
3
So who needs whom here?
Science minister Chris McDonald called the UK a natural home for AI and life sciences companies.
[18] He wants them turning research into jobs and growth.[18]
How it works
Economists call this a cluster: firms gather where talent, money and partners already are.
Afeyan said Flagship picks hubs with talent and capital.
[18] He said the UK has extraordinary depth of scientific talent.[18] Seen it before
A new cafe opens on the street that already has the crowds.
The truth
- The extra 500 million pounds is a hope that partners will join, not money committed.
[18]
-
Flagship Pioneering, whose companies include Moderna, has committed 100 million pounds to a company-building lab in London.
-
10
An Alzheimer's pill misses in the full trial
What happened
-
AriBio, a South Korean company, reported on 16 November that its Alzheimer's pill missed in its full final trial.
[19] -
Across all 1,535 patients, the pill slowed decline by 7%, too little to rule out chance.
[19] -
Among 604 patients taking no other Alzheimer's drugs, it slowed decline by 31%.
[19] -
The trial was designed with 2 main groups, so AriBio calls it positive.
[19]
How it unfolded
The pill, mirodenafil, has been sold in Korea for erection problems since 2007.
[19] - 2007 sold for erection problems
- 16 November Alzheimer's result
Why it matters
Unlike Leqembi and Kisunla, antibody drugs aimed at brain plaques, it would be a daily pill.
[19] Think it through
-
1
Is a win in one group a real win?
The smaller group had its own bar for chance, set before the trial, which it met.
[19] -
2
Did it reach its target in the brain?
It raised its chemical marker in spinal fluid in both groups.
[19] It did not change the measure of amyloid plaque.[19] Its markerraisedAmyloid plaqueunchanged -
3
So who decides what happens next?
Fosun Pharma, a Chinese drugmaker, paid $60 million for an option and has 90 days after full data to decide.
[19] Taking it triggers up to $180 million.[19] Million dollars
Paid for the option60Due if taken180Fosun's choice
How it works
Statisticians call a group named before results are seen a prespecified population.
[19] AriBio named the 604-patient group in advance, so its 31% result counts as a planned test.
[19] The idea, in story 06: Why a drug can hit its target and still not help →Seen it before
Calling heads before the coin lands is a guess; calling it after is only a report.
The truth
- A Cleveland Clinic study 12 years ago found 99.6% of Alzheimer's drug candidates failed, and the rate has barely moved.
[20] -
Nobody knows yet
Whether Fosun Pharma will take up AriBio's Alzheimer's pill.
Fosun has 90 days from receiving the full trial data to decide, and that data is not yet public.
[19]
What comes next
AriBio plans to discuss the results with the FDA.
[19] -
AriBio, a South Korean company, reported on 16 November that its Alzheimer's pill missed in its full final trial.
-
11
An eczema drug fails despite hitting its target
What happened
-
Aclaris Therapeutics said on Monday that its eczema drug bosakitug failed a mid-stage trial.
[21] -
Among 110 people with bad eczema, the drug did no better than a dummy at 24 weeks.
[21] -
The drug blocks TSLP, a molecule of the immune system.
[21] -
Aclaris dropped the drug, and its shares fell 5% to $3.73 before trading opened.
[21]
Why it matters
AstraZeneca, Amgen and Sanofi have also seen drugs against TSLP fail in eczema.
[21] Think it through
-
1
Did the drug even work in the body?
It did reach its target and lowered immune markers, yet the skin did not improve.
[21] Target reachedyesSkin betterno -
2
What is Aclaris betting on instead?
A two-target antibody, ATI-052, cut eczema scores 45% more than a dummy drug in an early test.
[21] Aclaris is aiming it first at a less crowded food-pipe disease.[21] 45%lower eczema score, early test
-
3
So what decides Aclaris's future now?
Guggenheim analysts say its pill modzatinib will drive the shares next year.
[21]
How it works
Pharmacologists call reaching the target target engagement: proof the drug arrived, not that it helps.
[21] Bosakitug engaged TSLP and lowered immune markers, but eczema scores did not change.
[21] That points at TSLP's role in eczema, not at the drug's aim.[21] The idea, in story 06: Why a drug can hit its target and still not help →Seen it before
Pressing the right lift button does nothing if the lift itself is broken.
The truth
- This is one trial of 110 people, but it matches earlier failures of TSLP drugs in eczema.
[21]
-
Aclaris Therapeutics said on Monday that its eczema drug bosakitug failed a mid-stage trial.
-
12
Kyntra drops its prostate cancer drug
What happened
-
Kyntra Bio, the company formerly called FibroGen, is ending a prostate cancer drug after a mid-stage trial.
[22] -
The drug, FG-3246, missed its goal in men whose cancer had spread and resisted hormone treatment.
[22] -
It was an antibody-drug conjugate, which links a targeting antibody to a toxin.
[15] -
Ending it saves more than $20 million over 2 years.
[22] -
Kyntra had just over $44 million at the end of September.
[22]
Why it matters
Kyntra now rests on roxadustat, an anaemia pill approved in Europe, Japan and China but not the US.
[22] Think it through
-
1
Why is the company so fragile?
The FDA rejected roxadustat for kidney disease, and the company settled US fraud allegations.
[22] -
2
So who decides whether it survives?
It needs a partner or new investors to start a final roxadustat trial planned for early 2027.
[22]
How it works
Drug developers call this a go/no-go decision: a set point where a drug that misses its goal is stopped.
FG-3246 had to clear an effectiveness bar in its phase 2 trial, and it did not, so Kyntra stopped it.
[22] Seen it before
A band that fails its audition does not get booked for the tour.
The truth
- Kyntra says its cash lasts through 2028, but its main trial still needs outside money to start.
[22]
-
Kyntra Bio, the company formerly called FibroGen, is ending a prostate cancer drug after a mid-stage trial.
-
13
Do weight-loss drugs protect the brain?
What happened
-
Researchers in Sweden and Denmark reviewed the evidence on drugs like Ozempic and the brain, in the journal Science.
[23] -
Health records link these drugs to less dementia in people with type 2 diabetes.
[23] -
But in Novo Nordisk's EVOKE trials, semaglutide, the drug in Ozempic, failed to slow early Alzheimer's.
[23] -
It changed several Alzheimer's markers but did not slow the disease.
[23]
Why it matters
It lands on people with obesity or diabetes, who sometimes struggle with attention and planning.
[23] Think it through
-
1
Why do records and trials disagree?
Records show who took the drug and stayed well, but cannot show the drug caused it.
[23] RecordsA linkNot a cause -
2
So could it help anyone's brain?
The authors think it may help thinking problems tied to obesity and diabetes, not Alzheimer's itself.
[23] Obesity-linked thinkingmay helpAlzheimer'sdid not slow -
3
So what would settle it?
Trials that test memory and attention from the first dose, the authors say.
[23]
How it works
Epidemiologists call record-based studies observational: they watch what happened, without assigning the drug.
[23] Here, observational records linked the drugs to less dementia, but the EVOKE trials, which assigned the drug, found no slowing.
[23] The idea, in story 06: Why a drug can hit its target and still not help →Seen it before
Children who own more books tend to read better, but buying books alone may not be what helps.
The truth
- This is a review of other studies, not a new trial.
[23] Fast weight loss can cost frail older people muscle, the authors warn.[23]
-
Researchers in Sweden and Denmark reviewed the evidence on drugs like Ozempic and the brain, in the journal Science.
-
14
The FDA shares its drug reviews abroad
What happened
-
The FDA launched a programme to share its drug approval reviews with regulators in other countries.
[24] -
Companies can pass the lightly blacked-out files to foreign regulators.
[24] Those regulators can rely on them instead of repeating the work.[24] -
It began on 30 October with lenacapavir, an HIV drug for prevention and treatment.
[24] -
It will widen to all new drugs in January 2027.
[24]
Who is involved
That approval was for PEPFAR, the US relief plan against AIDS.
[24] How it unfolded
- 30 October starts with lenacapavir
- January 2027 all new drugs
Why it matters
Patients in poorer countries can wait months or years while their own regulator repeats a review.
[24] Think it through
-
1
Do other countries have to follow the FDA?
No: each keeps the final say over its own decision, the FDA says.
[24] -
2
Why would the FDA do this?
An FDA deputy commissioner, Grace Graham, praised it as America First policies improving public health worldwide.
[24] -
3
So who controls the files?
Companies hold the key: only they receive the files, and they choose which regulators see them.
[24]
How it works
Regulatory scientists call this reliance: one regulator leaning on another's review instead of redoing it.
[24] Under the programme, a foreign regulator can rely on the FDA's detailed review of lenacapavir rather than repeat it.
[24] Seen it before
A school accepts another school's exam marks instead of making a pupil sit the test again.
The truth
- Only companies get the files; anyone else must file a freedom-of-information request.
[24]
-
The FDA launched a programme to share its drug approval reviews with regulators in other countries.
-
15
NIH's infectious disease arm gets a permanent head
What happened
-
John Powers III was named permanent director of NIAID, the NIH's branch for allergy and infectious diseases.
[6] -
He has run it as acting director since June.
[6]
Who is involved
The NIH is the US government's medical research agency.
[6] How it unfolded
It had had no permanent head since Jeanne Marrazzo was forced out in 2025 for objecting to grant cuts.
[6] Anthony Fauci ran the institute for nearly 4 decades.
[6] - June acting director
- This week permanent director
Why it matters
This year he co-wrote a paper with NIH director Jay Bhattacharya.
[6] It urged NIAID to move away from HIV and pandemic preparedness.[6] Think it through
-
1
Why is this agency so watched?
Republicans looking to re-argue the Covid pandemic have made it a main target, STAT reports.
[6] -
2
Who loses if the focus moves?
HIV and pandemic research would lose priority under the plan in that paper.
[6] HIV and pandemicslower priorityBroader infectionshigher priority -
3
So who sets NIAID's course now?
Powers runs it under NIH director Jay Bhattacharya, and the two co-wrote the plan to shift its focus.
[6]
How it works
Science policy scholars call this priority setting: deciding which diseases get research money first.
Powers's priority setting, with Bhattacharya, puts broader infections and immunology ahead of HIV and pandemic preparedness.
[6] Seen it before
A family choosing which bills to pay first decides what gets cut.
The truth
- The clearest sign of his plans so far is the paper he co-wrote calling for a move away from HIV.
[6]
-
John Powers III was named permanent director of NIAID, the NIH's branch for allergy and infectious diseases.
-
16
Alcohol weakens cancer immunotherapy in mice
What happened
-
Alcohol cut the effect of a common cancer immunotherapy by about 50% in mice, a study in Science Signaling found.
[25] -
The drugs, anti-PD-1 antibodies, work through T cells, the immune cells that attack tumours.
[25] -
In mice with bladder tumours, alcohol cut the number of T cells inside the tumours.
[25] -
In patients, those reporting 8 or more drinks a week had poorer survival after treatment.
[25] -
As many as 76.4% of people with cancer still drink, studies suggest.
[25]
Why it matters
Medical societies have asked for research on how alcohol affects cancer treatment.
[25] Think it through
-
1
Can the damage be undone?
In mice, blocking a second brake, TIGIT, restored the drug's effect.
[25] Block TIGIT tooT cells free againDrug works again -
2
Does it hold in people?
The patient data were looked back on and self-reported, and were clearest only in lung cancer.
[25] -
3
So what would settle it?
The authors want drinking recorded in cancer databases, to test it across treatments.
[25]
How it works
Immunologists call PD-1 a checkpoint: a brake on T cells that tumours can press.
[25] Alcohol raised TIGIT, another checkpoint, on T cells, so lifting the PD-1 brake alone did less.
[25] Seen it before
Letting off a car's handbrake does little if a second brake is still on.
The truth
- The 50% cut was measured in mice; the human data came from patients' own reports of drinking.
[25]
-
Alcohol cut the effect of a common cancer immunotherapy by about 50% in mice, a study in Science Signaling found.
-
17
Over 116,000 kinds of gut virus mapped
What happened
-
King's College London researchers found over 116,000 groups of viruses living in the human gut.
[26] -
More than 99% had no close match in the largest existing catalogue of gut viruses.
[26] -
The team used data from over 1,000 twins in the TwinsUK study.
[26] -
Genes explained around 47% of the differences in overall viral variety.
[26]
Who is involved
Many are bacteriophages, viruses that infect bacteria rather than people.
[26] Why it matters
A second study, in the journal Gut, linked 50 viral groups to irritable bowel syndrome.
[26] The condition affects about 10% of people.[26] Think it through
-
1
Do the viruses cause IBS?
Not shown: the researchers say they cannot yet tell whether the viruses drive the changes.
[26] -
2
So what would they need to show?
That the viruses change what gut bacteria make, which the team says it will test next.
[26] VirusesChange bacteria?Change gut chemicals?
How it works
Microbiologists call the gut's whole mix of microbes the gut microbiome.
[26] Here the viruses tracked the bacteria they infect, and the chemicals those bacteria make.
[26] Seen it before
Noting who sits near whom in a canteen shows friendships, not who started them.
The truth
- Twin studies separate genes from surroundings, but these links are matches, not proven causes.
[26]
-
King's College London researchers found over 116,000 groups of viruses living in the human gut.
-
18
Human blood stem cells don't act like mouse ones
What happened
-
University of Southern California researchers tagged single human blood stem cells with genetic barcodes and tracked them in mice.
[27] -
Conditioning changed which blood cells grew back and how fast, but not whether donor cells took hold.
[27] -
Human progenitor cells, seen as short-lived from mouse work, kept making blood longer than expected.
[27]
Who is involved
Blood stem cells make the body's blood and immune cells, and are central to bone marrow transplants.
[27] Before a transplant, patients get chemotherapy or radiation to clear room, called conditioning.
[27] Why it matters
Bone marrow transplants treat leukaemia, lymphoma and some inherited blood disorders.
[27] Think it through
-
1
Why did the mouse studies mislead?
Most of what was known came from mouse cells.
[27] Human cells do not always behave as mouse studies predict, the lead researcher said.[27] Mouse cellswell studiedHuman cellsbehave differently -
2
So who could use this?
Doctors could one day tailor conditioning to each patient, though this is not yet tested in people.
[27]
How it works
Stem cell biologists call this clonal tracking: tagging a cell so all its offspring can be counted.
[27] Each human stem cell carried its own barcode, so the team could count the blood cells it produced.
[27] Seen it before
Stamping each seed packet's number on its plants shows which seeds grew most.
The truth
- It was done in mice given human cells, so whether patients respond the same way is unknown.
[27]
-
University of Southern California researchers tagged single human blood stem cells with genetic barcodes and tracked them in mice.
-
19
UN warns on hormone-disrupting chemicals
What happened
-
Two UN bodies warned on Tuesday that chemicals that disrupt hormones are a growing threat to health.
[28] -
They are found in plastics, cosmetics, toys, electronics and pesticides.
[28] -
They have been found in breast milk and in umbilical cord blood.
[28] -
Of over 350,000 chemicals registered worldwide, most have never been tested for hormone effects.
[28] -
The EU has officially identified 231, with 121 more under review.
[28]
Why it matters
Exposure in the womb or early childhood can affect brain development, growth and fertility, the UN says.
[28] Think it through
-
1
Why hasn't regulation caught up?
Most testing has not led to rules controlling exposure, a lead author, Laura Vandenberg, said.
[28] Chemicals testedNo rules followExposure goes on -
2
What happens when one is dropped?
Makers often swap in a similar, less-tested chemical, which Vandenberg called a whack-a-mole problem.
[28] One chemical droppedA similar one swapped inProblem returns -
3
So who has to act?
Regulators, the report says, should protect pregnancy and childhood first.
[28] It also wants the costs of exposure counted.[28]
How it works
Toxicologists call these endocrine disruptors: chemicals that interfere with the body's hormone systems.
[28] BPA, used in food containers, was dropped when buyers shunned it, but similar chemicals replaced it.
[28] Seen it before
Swapping one sugar in a recipe for another does not make the cake any less sweet.
The truth
- Regulation still judges most chemicals one at a time, ignoring their combined effect, a chapter author said.
[28]
-
Two UN bodies warned on Tuesday that chemicals that disrupt hormones are a growing threat to health.
-
20
Court strikes down a US time cap on student visas
What happened
-
A US federal judge in Boston struck down a plan to cap how long foreign students and scholars can stay.
[29] -
The US Department of Homeland Security had proposed in July a 4-year limit, unless students won federal approval.
[29] -
Judge Dennis Saylor called the rule arbitrary, capricious and an abuse of discretion.
[29]
Why it matters
International researchers make up about 60% of US postdoctoral researchers, STAT reports.
[6] Think it through
-
1
Why does biotech care about student visas?
Foreign researchers are also nearly a quarter of US life science PhD graduates.
[6] -
2
So is the cap gone for good?
The US government had appealed an earlier ruling, so a higher court may still weigh in.
[29]
How it works
In US law, a court can strike down a rule it finds arbitrary and capricious.
[29] Saylor found US Homeland Security had no power to undercut a visa the US Congress meant to encourage.
[29] Seen it before
A referee can overturn a club rule that breaks the league's rulebook.
The truth
- A lead plaintiff said foreign student numbers are already falling under the Trump administration's policies.
[29]
-
A US federal judge in Boston struck down a plan to cap how long foreign students and scholars can stay.
-
21
Regeneron's antibody eases POTS in a trial
What happened
-
Regeneron said its antibody baloncibart eased POTS, a condition where the heart races on standing, in a mid-stage trial.
[30] -
The trial gave 82 patients one of 2 doses or a dummy drug.
[30] -
On day 8, the bigger dose cut the heart's jump on standing by 11.4 beats a minute, against the dummy.
[30] -
By day 29 the gap was 7.4 beats a minute.
[30] The smaller dose's effect had faded by then.[30]
Who is involved
POTS can also bring tiredness, pain and trouble thinking.
[30] Why it matters
There is no FDA-approved treatment for POTS, which Regeneron says affects 500,000 to several million people in the US.
[30] Think it through
-
1
Why would an antibody calm the heart?
Regeneron bet that blocking a protein called NPR1 would raise the amount of blood in circulation.
[30] Block NPR1More blood in circulationHeart races less -
2
What did patients pay for it?
Side effects hit 67.9% on the bigger dose and 48.1% on the dummy, mostly mild or moderate.
[30] % with side effects
Bigger dose67.9Dummy drug48.1side effects in the trial -
3
So who moves next?
Regeneron does, with a final-stage trial planned for the first half of 2027.
[30]
How it works
Pharmacologists call a drug's first test of its idea in patients proof of concept. It asks whether hitting the target moves the illness.
Here, blood markers moved as expected on day 8, and standing heart rate fell too.
[30] So hitting NPR1 did move POTS in this trial.[30] Seen it before
Adding water to a garden hose raises the pressure, so the tap does not have to work as hard.
The truth
- The result comes from 82 patients over about a month, so lasting benefit is unproven.
[30]
-
Regeneron said its antibody baloncibart eased POTS, a condition where the heart races on standing, in a mid-stage trial.
-
22
Kyverna files for the first autoimmune CAR-T
What happened
-
Kyverna Therapeutics has finished its FDA application for miv-cel, a CAR-T treatment, in stiff person syndrome.
[31] -
If approved, miv-cel would be the first CAR-T approved for an autoimmune disease, where the body attacks itself.
[31] -
Kyverna asked for priority review and is preparing for a possible launch in 2027.
[31] -
At the same time it dropped KYV-102, a follow-up made from whole blood.
[31]
Who is involved
CAR-T means taking a patient's own immune T cells and changing them to attack a chosen target.
[31] How it unfolded
- This week application finished
- 2027 possible launch
Why it matters
It lands on people with stiff person syndrome and other immune diseases of the nerves.
[31] Think it through
-
1
What was the follow-up for?
KYV-102 skipped apheresis, where T cells are filtered out of a patient's blood, so more patients could get it.
[31] miv-celneeds apheresisKYV-102made from whole blood -
2
So why drop it now?
Kyverna says it will focus on getting miv-cel through late-stage nerve-disease trials.
[31] -
3
So who holds the next step?
The FDA decides on the application, and Kyverna is already lining up specialists and payers for a launch.
[31]
How it works
Immunologists call a marker on a cell's surface an antigen, and engineered CAR-T cells hunt every cell carrying theirs.
Miv-cel's chosen antigen is CD19, so its engineered cells hunt cells that carry it.
[31] Seen it before
Wiping a hard drive and reinstalling fresh software can clear a fault that kept coming back.
The truth
- Kyverna gave no reason for dropping KYV-102 beyond its focus, and Fierce Biotech asked for more.
[31]
-
Kyverna Therapeutics has finished its FDA application for miv-cel, a CAR-T treatment, in stiff person syndrome.
More Biotech editions
Across the beats